Developing differentiated & improved therapies
for patients with autoimmune & inflammatory diseases
who have limited treatment options
who have limited treatment options
ValenzaBio is a privately held clinical-stage biopharmaceutical company developing safe, effective, and differentiated therapies for autoimmune and inflammatory diseases. The company’s pipeline of monoclonal antibodies features best-in-class properties, targeting clinically validated mechanisms, and will provide improved treatment options for patients.
Explore our lead product candidates
VB119
An anti-CD19 monoclonal antibody currently enrolling clinical trials in renal autoimmune indications
more
News